406 related articles for article (PubMed ID: 30506540)
1. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
Qi C; Pan F; Li J; Li Y; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
[No Abstract] [Full Text] [Related]
3. [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].
Sun XF; Gao XD; Yuan W; Sun JY; Fu M; Xue AW; Li H; Shu P; Fang Y; Hou YY; Shen KT; Sun YH; Qin J; Qin XY
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):880-887. PubMed ID: 32927513
[No Abstract] [Full Text] [Related]
4. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
6. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK
Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666
[TBL] [Abstract][Full Text] [Related]
7. Extra-gastrointestinal stromal tumor arising in the lesser omentum with a platelet-derived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review.
Kanamori K; Yamagata Y; Honma Y; Date K; Wada T; Hayashi T; Otsuki S; Sekine S; Yoshikawa T; Katai H; Nishida T
World J Surg Oncol; 2020 Jul; 18(1):183. PubMed ID: 32703220
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
[TBL] [Abstract][Full Text] [Related]
9. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
11. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
[TBL] [Abstract][Full Text] [Related]
12. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
13. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Ali Abuderman AW; M Aldakheel F
Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
15. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
Indio V; Astolfi A; Tarantino G; Urbini M; Patterson J; Nannini M; Saponara M; Gatto L; Santini D; do Valle IF; Castellani G; Remondini D; Fiorentino M; von Mehren M; Brandi G; Biasco G; Heinrich MC; Pantaleo MA
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510530
[TBL] [Abstract][Full Text] [Related]
16. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD
Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936
[TBL] [Abstract][Full Text] [Related]
17. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
18. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Heinrich MC; Griffith D; McKinley A; Patterson J; Presnell A; Ramachandran A; Debiec-Rychter M
Clin Cancer Res; 2012 Aug; 18(16):4375-84. PubMed ID: 22745105
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
20. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Cassier PA; Fumagalli E; Rutkowski P; Schöffski P; Van Glabbeke M; Debiec-Rychter M; Emile JF; Duffaud F; Martin-Broto J; Landi B; Adenis A; Bertucci F; Bompas E; Bouché O; Leyvraz S; Judson I; Verweij J; Casali P; Blay JY; Hohenberger P;
Clin Cancer Res; 2012 Aug; 18(16):4458-64. PubMed ID: 22718859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]